Comparison of the Effects of Cholesterol, Palmitic Acid, and Glucose on Activation of Human Hepatic Stellate Cells to Induce Liver Fibrosis

Overview

Journal J Diabetes Metab Disord

Specialty Endocrinology

Date 2022 Nov 21

PMID 36404864

Authors

Ghorban Mohammadzadeh

Reza Afarin

Samaneh Salehipour Bavarsad

Fereshteh Aslani

Shahla Asadi Zadeh

Elham Shakerian

Affiliations

Soon will be listed here.

Abstract

Background: In hepatic damage, Hepatic stellate cells (HSCs) become active, proliferate, and change to myofibroblasts. Increasing the fibrogenic genes, such as Transforming growth factor-β (TGF-β), Alpha Smooth Muscle Actin (α-SMA), and Collagen1 α (COL 1α) show that the activation of HSCs can lead to hepatic fibrosis.

Purpose: These days people consume much cholesterol, palmitic acid, and glucose which can have adverse effects on an individuals' health, but their influences on activating human HSCs and inducing liver fibrosis have not been assessed. Our purpose is to investigate the effects of these three main and abundant ingredients in the diet on the activation of human HSCs and inducing liver fibrosis.

Methods: To measure cholesterol, palmitic acid, and glucose cytotoxic effects on the viability of the cells, the MTT technique was used. Then the treated cells were incubated in media containing cholesterol, palmitic acid, and glucose with different concentrations for 24 h. At last, the α-SMA, COL 1α, and TGF-β, genes mRNA expression were measured by real-time PCR.

Results And conclusions: Our results demonstrated that high concentrations of cholesterol and palmitic acid can activate human HSCs that lead to an increase in the mRNA expressions of fibrogenic genes. Thus, controlling fat intaking and knowing its mechanism is crucial to prevent and attenuate hepatic fibrosis.

Citing Articles

Unraveling the Exosome-miR-133a Axis: Targeting TGF-β Signaling via WJ-MSC-Derived Exosomes for Anti-Fibrotic Therapy in Liver Fibrosis.

Saki S, Monjezi S, Ghaffari F, Orak G, Salehipour Bavarsad S, Khedri A Iran Biomed J. 2024; 28(5 & 6):235-44.

PMID: 39629623 PMC: 11829155. DOI: 10.61186/ibj.4357.

NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay.

Cernea S Life (Basel). 2024; 14(2).

PMID: 38398781 PMC: 10890557. DOI: 10.3390/life14020272.

The Effect of Lipopolysaccharide-Stimulated Adipose-Derived Mesenchymal Stem Cells on NAFLD Treatment in High-Fat Diet-Fed Rats.

Afarin R, Aslani F, Asadizade S, Jaberian Asl B, Mohammadi Gahrooie M, Shakerian E Iran J Pharm Res. 2023; 22(1):e134807.

PMID: 38116551 PMC: 10728850. DOI: 10.5812/ijpr-134807.

Effects of exosomes of mesenchymal stem cells on cholesterol-induced hepatic fibrogenesis.

Rashidi M, Matour E, Monjezi S, Asadi Zadeh S, Shakerian E, Sabahy S Iran J Basic Med Sci. 2023; 26(6):695-700.

PMID: 37275763 PMC: 10237171. DOI: 10.22038/IJBMS.2023.68858.15003.

Exosomes of Whartons' jelly mesenchymal stem cell reduce the NOX genes in TGF-β-induced hepatic fibrosis.

Afarin R, Behdarvand T, Shakerian E, Salehipour Bavarsad S, Rashidi M Iran J Basic Med Sci. 2022; 25(12):1498-1503.

PMID: 36544529 PMC: 9742568. DOI: 10.22038/IJBMS.2022.66802.14649.

References

Wells R . The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol. 2005; 39(4 Suppl 2):S158-61. DOI: 10.1097/01.mcg.0000155516.02468.0f. View

Liu X, Hu H, Yin J . Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 2006; 26(1):8-22. DOI: 10.1111/j.1478-3231.2005.01192.x. View

Liu Z, Li C, Kang N, Malhi H, Shah V, Maiers J . Transforming growth factor β (TGFβ) cross-talk with the unfolded protein response is critical for hepatic stellate cell activation. J Biol Chem. 2019; 294(9):3137-3151. PMC: 6398135. DOI: 10.1074/jbc.RA118.005761. View

Krizhanovsky V, Yon M, Dickins R, Hearn S, Simon J, Miething C . Senescence of activated stellate cells limits liver fibrosis. Cell. 2008; 134(4):657-67. PMC: 3073300. DOI: 10.1016/j.cell.2008.06.049. View

Kiss K, Regos E, Rada K, Firneisz G, Baghy K, Kovalszky I . Chronic Hyperglycaemia Induced Alterations of Hepatic Stellate Cells Differ from the Effect of TGFB1, and Point toward Metabolic Stress. Pathol Oncol Res. 2018; 26(1):291-299. DOI: 10.1007/s12253-018-0458-9. View

Altamirano-Barrera A, Barranco-Fragoso B, Mendez-Sanchez N . Management strategies for liver fibrosis. Ann Hepatol. 2017; 16(1):48-56. DOI: 10.5604/16652681.1226814. View

Iredale J . Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol Res. 2008; 58(2):129-36. DOI: 10.1016/j.phrs.2008.06.011. View

Kweon Y, Paik Y, Schnabl B, Qian T, Lemasters J, Brenner D . Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol. 2003; 39(1):38-46. DOI: 10.1016/s0168-8278(03)00178-8. View

Perez-Carreras M, del Hoyo P, Martin M, Rubio J, Martin A, Castellano G . Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003; 38(4):999-1007. DOI: 10.1053/jhep.2003.50398. View

10.

Sumiyoshi M, Sakanaka M, Kimura Y . Chronic intake of a high-cholesterol diet resulted in hepatic steatosis, focal nodular hyperplasia and fibrosis in non-obese mice. Br J Nutr. 2009; 103(3):378-85. DOI: 10.1017/S0007114509991772. View

11.

BISSELL D, Roulot D, George J . Transforming growth factor beta and the liver. Hepatology. 2001; 34(5):859-67. DOI: 10.1053/jhep.2001.28457. View

12.

Reeves H, Burt A, Wood S, Day C . Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol. 1996; 25(5):677-83. DOI: 10.1016/s0168-8278(96)80238-8. View

13.

Vazquez-Jimenez J, Chavez-Reyes J, Romero-Garcia T, Zarain-Herzberg A, Valdes-Flores J, Manuel Galindo-Rosales J . Palmitic acid but not palmitoleic acid induces insulin resistance in a human endothelial cell line by decreasing SERCA pump expression. Cell Signal. 2015; 28(1):53-9. DOI: 10.1016/j.cellsig.2015.10.001. View

14.

Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M . Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005; 37(5):349-56. DOI: 10.1016/j.dld.2004.11.009. View

15.

Roehlen N, Crouchet E, Baumert T . Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020; 9(4). PMC: 7226751. DOI: 10.3390/cells9040875. View

16.

Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y . Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol. 2006; 41(10):971-80. DOI: 10.1007/s00535-006-1883-1. View

17.

Friedman S, Maher J, BISSELL D . Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology. 2000; 32(6):1403-8. DOI: 10.1053/jhep.2000.20243. View

18.

Zhou L, Liu S, Han M, Ma Y, Feng S, Zhao J . miR-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis. Mol Ther Nucleic Acids. 2018; 10:91-102. PMC: 5735261. DOI: 10.1016/j.omtn.2017.11.010. View

19.

Martin M, Lefaix J, Delanian S . TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?. Int J Radiat Oncol Biol Phys. 2000; 47(2):277-90. DOI: 10.1016/s0360-3016(00)00435-1. View

20.

Kleinfeld A, Prothro D, Brown D, Davis R, Richieri G, DeMaria A . Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol. 1996; 78(12):1350-4. DOI: 10.1016/s0002-9149(96)00651-0. View